- ORIC Pharmaceuticals Inc ORIC entered a clinical development collaboration for a potential Phase 2 study of ORIC-533 in multiple myeloma with Pfizer Inc PFE and agreed to sell around 5.4 million shares at $4.65 per share for gross proceeds of approximately $25.0 million.
- The company will use the net proceeds to fund ongoing and planned clinical trials, including studies of ORIC-533, ORIC-114, and ORIC-944, and for working capital and general corporate purposes.
- ORIC and Pfizer have entered into a clinical development collaboration to leverage Pfizer's global development capabilities and expertise to enhance the clinical development program for ORIC-533, an oral small molecule inhibitor of CD73.
- The companies will advance ORIC-533 into a Phase 2 combination study with Pfizer's elranatamab for multiple myeloma.
- ORIC will maintain full economic ownership and control of ORIC-533.
- In conjunction with the investment, Jeff Settleman, Chief Scientific Officer, Oncology Research & Development, Pfizer, will join ORIC's Scientific Advisory Board.
- Including Pfizer's equity investment, ORIC expects its cash runway to be extended into the first half of 2025.
- Price Action: ORIC shares are up 51.70% at $4.55 during the premarket session on the last check Thursday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Posted In: BiotechLarge CapNewsPenny StocksHealth CareFinancingOfferingsContractsMoversTrading IdeasGeneralBriefswhy it's moving
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in